Penile ulcerations with foscarnet

Fégueux, S.; Salmon, D; Picard, Catherine; Sauvage, C.; Longuet, P; Desmoulins, TH; Moyle, Graeme; Barton, Samantha; Balestrini, A. E.; Nelson, Marvin C.; Youle, Michael; Hawkins, D. F.; Gazzard, Brian; Lernestedt, John-Olof; Chanas, Anna

doi:10.1016/0140-6736(90)90786-5

Cited by 30 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIV-positive individuals also have an increased propensity to develop drug-induced phototoxic lichenoid eruptions in which erythematous patches and plaques develop at light exposed sites; drugs frequently implicated include non-steroidal antiin¯ammatory agents, dapsone and trimethoprim± sulfamethoxazole. Other unusual drug eruptions reported to occur in HIV disease include the commonly encountered zidovudine (AZT)-induced nail and oral pigmentation and rarely a lichen planus-like eruption 21 , penile ulcerations caused by foscarnet 22 and injection-site ulceration caused by intramuscular pentamidine 23 . Protease inhibitors may induce a dose-limiting fat redistribution lipodystrophy that gives an appearance similar to Cushing's disease in the absence of deranged corticosteroid levels 24 .…”

Section: Drug Eruptionsmentioning

confidence: 99%

The management of HIV-related skin disease Part II: Neoplasms and inflammatory disorders

Osborne

Taylor

Fuller³

2003

Int J STD AIDS

View full text Add to dashboard Cite

Section: Drug Eruptionsmentioning

confidence: 99%

The management of HIV-related skin disease Part II: Neoplasms and inflammatory disorders

Osborne

Taylor

Fuller³

2003

Int J STD AIDS

View full text Add to dashboard Cite

“…It appears that foscamet chelates divalent metal ions such as calcium, resulting in a doserelated but reversible drop in serum calcium that may be severe or even fatal (223). Penile ulcers have also been seen with systemic therapy and may result from the localized irritant effect of high levels of ionized foscamet in the urine (136,168,276,319,482).…”

Section: Foscarnetmentioning

confidence: 99%

Antiviral therapy: current concepts and practices.

Bean

1992

Clinical Microbiology Reviews

View full text Add to dashboard Cite

Section: Foscarnetmentioning

confidence: 99%

Antiviral therapy: current concepts and practices

Bean

1992

Clin Microbiol Rev

View full text Add to dashboard Cite

Drugs capable of inhibiting viruses in vitro were described in the 1950s, but real progress was not made until the 1970s, when agents capable of inhibiting virus-specific enzymes were first identified. The last decade has seen rapid progress in both our understanding of antiviral therapy and the number of antiviral agents on the market. Amantadine and ribavirin are available for treatment of viral respiratory infections. Vidarabine, acyclovir, ganciclovir, and foscarnet are used for systemic treatment of herpesvirus infections, while ophthalmic preparations of idoxuridine, trifluorothymidine, and vidarabine are available for herpes keratitis. For treatment of human immunodeficiency virus infections, zidovudine and didanosine are used. Immunomodulators, such as interferons and colony-stimulating factors, and immunoglobulins are being used increasingly for viral illnesses. While resistance to antiviral drugs has been seen, especially among AIDS patients, it has not become widespread and is being intensely studied. Increasingly, combinations of agents are being used: to achieve synergistic inhibition of viruses, to delay or prevent resistance, and to decrease dosages of toxic drugs. New approaches, such as liposomes carrying antiviral drugs and computer-aided drug design, are exciting and promising prospects for the future.

show abstract

Penile ulcerations with foscarnet

Cited by 30 publications

References 6 publications

The management of HIV-related skin disease Part II: Neoplasms and inflammatory disorders

The management of HIV-related skin disease Part II: Neoplasms and inflammatory disorders

Antiviral therapy: current concepts and practices.

Antiviral therapy: current concepts and practices

Contact Info

Product

Resources

About